Related Party Transactions (Details) - Related party |
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2025
item
shares
|
Dec. 31, 2020
shares
|
|
| Xencor | ||
| Related Party Transactions | ||
| Number of antibody product candidates | 3 | |
| Number of license agreements | 2 | |
| Xencor | Maximum | ||
| Related Party Transactions | ||
| Ownership percentage by related party | 10.00% | |
| Viridian | ||
| Related Party Transactions | ||
| Ownership percentage by related party | 0.10% | |
| Number of common stock issued | shares | 38,707 | |
| Viridian | Fairmount Funds Management LLC | ||
| Related Party Transactions | ||
| Number of seats held in board | 2 | |
| Viridian | Fairmount Funds Management LLC | Maximum | ||
| Related Party Transactions | ||
| Ownership percentage by related party | 10.00% | |
| InnoCare | ||
| Related Party Transactions | ||
| Number of common stock issued | shares | 5,000,000 | |
| Number of products | 3,000 | |
| Number of shares issued | shares | 2,000,000 | |
| InnoCare | Maximum | ||
| Related Party Transactions | ||
| Ownership percentage by related party | 10.00% | |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of seats held in the board of related entity. No definition available.
|
| X | ||||||||||
- Definition Represents the number of shares to be issued. No definition available.
|
| X | ||||||||||
- Definition The percentage of ownership of the entity's common stock by a related party. No definition available.
|
| X | ||||||||||
- Definition Number of antibody product candidates for which license has been obtained. No definition available.
|
| X | ||||||||||
- Definition Number of license agreements. No definition available.
|
| X | ||||||||||
- Definition Represents the number of products for which we obtained rights to develop, manufacture and commercialize. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|